Cougar Puberty Club Smart. Cheeky. Honest. Perimenopause, for real.

Flow Space - The Midlife Microdosing Boom: Why Women Are Trying Magic Mushrooms (Aug 2026)

Tier 3: Supporting source (media, company, or community), never used alone for health claims
Publisher: Flow Space (Penske Media Corporation) · Published: August 5, 2026 · Accessed: August 14, 2026

Visit the source ↗

Claims this source supports

  • Flow Space reports a growing number of midlife women microdosing psilocybin (sub-hallucinogenic doses, typically one-tenth to one-twentieth of a recreational dose) to manage stress, mood, cognitive fog and identity reset - reporting an example of a 45-year-old taking 100mg capsules in morning tea three to four times a week.
  • Flow Space quotes neuroscientist Rachel Yehuda (Icahn School of Medicine at Mount Sinai): blinded, placebo-controlled studies 'generally have not produced reliable improvements in attention, creativity, thinking or emotional functioning' from microdosing, and there is not enough evidence to assume a microdose is a miniature version of psychedelic therapy.
  • Flow Space reports there is no evidence psychedelics are effective treatments for perimenopause or menopause symptoms, and no controlled trials investigating it.
  • Flow Space reports pre-clinical research in female rodents suggests lower estrogen levels translated to duller behavioral responses to psilocybin and higher levels caused more intense effects - estrogen modulates the brain's serotonin system, which psilocybin acts on.
  • Flow Space reports psilocybin has been a Schedule I controlled substance at the US federal level since the 1970s; New Mexico, Colorado and Oregon have legalized it to some degree; a handful of cities in California, Michigan, Washington plus Denver have decriminalized it; Washington D.C. de-prioritized enforcement in 2021.
  • Flow Space reports RAND data that 11 million American adults used psilocybin in 2025, that 69% of psilocybin users microdosed at least once, and that observational studies show nearly 70% of exclusive microdosers are women, with an average age of 46.6.
  • Flow Space reports interest is being backed by investment and policy shifts: a presidential executive order to fast-track psychedelic research, ~$10M Department of Defense allocation for MDMA/PTSD study, and Eli Lilly's $2.8B acquisition of a psychedelic-drug company.